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hereditary spherocytosis

OPSS

overwhelming post-splenectomy spherocytosis

TS

total splenectomy

PS

partial splenectomy

Abstract
To compare the clinical effectiveness of total (TS) or partial (PS) splenectomy in pediatric
hereditary spherocytosis, a systematic review and meta-analysis was performed (PROSPERO
registration CRD42015030056). There were 14 observational studies comparing pre- and postoperative hematologic parameters. Secondary outcomes include in-hospital infections, surgical
complications, symptomatic recurrence and biliary disease. TS is more effective than PS to
increase hemoglobin (3.6 g/dL vs 2.2 g/dL) and reduce reticulocytes (12.5% vs 6.5%) after one
year; outcomes following PS are stable for at least 6 years. There were no cases of overwhelming
post-splenectomy sepsis. A population-based patient registry is needed for long-term follow-up.

Introduction
Hereditary spherocytosis (HS) is a rare genetic disease affecting the erythrocyte cell
membrane, producing characteristically spherical erythrocytes (spherocytes). The worldwide
prevalence of HS is approximately 1 in 2,000 people [1–3]. The main molecular defects in HS
arise from a heterogeneous set of mutations to cytoskeletal proteins facilitating linkage to the lipid
bilayer [4], Weakening the mechanical integrity of the cell membrane. Signs and symptoms of HS
may include splenomegaly, severe anemia, jaundice, reticulocytosis, fatigue, abdominal
discomfort [5]. These symptoms are widely recognized to be caused by hemolysis of immature
reticulocytes undergoing conditioning in the spleen.
The degree of splenomegaly is a generally reliable indicator of the severity of hemolysis,
anemia and risk of developing gall stones. An enlarged spleen is also vulnerable to traumatic
rupture. If the degree of anemia is too great, surgical management of HS by splenectomy remains
the only intervention. Management of HS by splenectomy has historically been focused on total
splenectomy (TS) which was performed through a laparotomy incision. In the early 1990s, the
laparoscopic approach was successfully adopted for splenectomy in HS patients [6], and became
a more popular choice of technique. The spleen is a major lymphoid organ in the body and the risk
of infection caused by staphylococci and Gram-negative enteric organisms is high in the early
post-operative period. Following TS, there is increased susceptibility for many years to potentially
fatal overwhelming post-splenectomy sepsis (OPSS; otherwise called overwhelming postsplenectomy infection) from these encapsulated bacteria such as pneumococci, Neisseria
meningitides, Haemophilus influenzae and staphylococci [7]. The risk of OPSS from these
organisms has been reduced as most centres across North America and Europe use prophylactic
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vaccinations and prophylactic antibiotics prior to elective splenectomy, and if possible, delay the
surgery until the patient over five years old [4]. It is suggested that PS confers some residual
immune competence against encapsulated organisms. The level of circulating IgM memory B cells
after splenectomy and the percentage of pitted erythrocytes have been used as surrogate markers
for immune competence against encapsulated organisms or residual splenic function [8, 9].
However, these observations need further validation through prospective, controlled studies. This
review aims to determine how PS and TS compare when performed for pediatric HS.
Methods
Systematic Review Protocol
Methods of the present systematic review and meta-analysis were pre-specified and
documented in a protocol (PROSPERO registration CRD42015030056). The study question was
translated into a PICO-formatted grid and was developed to guide the selection of appropriate
search terms (Table I), in accordance with the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines [10] (Supplemental Table SI).
The population of interest (P) were children, 18 years of age or younger, diagnosed with
HS. The intervention (I) was a PS as compared (C) to TS, performed to correct anemia, the primary
indicator of HS severity. While PS can be performed as one of two surgical procedures, a less
aggressive PS and a more aggressive near-total splenectomy, both are treated as PS for this review.
The former leaves between a splenic remnant of about 15-30% in size; the latter leaves a splenic
remnant supplied by a single pedicle, of about 10-15% [11]. This choice is left to the experience
of surgeon. The specific surgical technique was not considered here. Primary outcomes (O),
chosen based on a pilot search, were pre- and post-operative hemoglobin concentration (g/dL) and
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percent reticulocytes because these are the most commonly reported outcomes, and often only with
one year of follow-up; these were of primary interest because they are a marker of anemia and
erythropoiesis, respectively. Secondary outcomes included in-hospital infections, surgical
complications, biliary disease, OPSS, recurrence of symptoms and splenosis. All study designs (S)
were included for initial screening except case-series with less than five cases.
Search Strategy
A systematic literature search protocol was conducted with the help of a research librarian
using the PubMed, EMBASE, Web of Science and CINAHL databases up to Oct. 1, 2015 for
studies published with English full-text. Search terms regarding the population of interest,
intervention and indication, and comparator and outcome were used to identify eligible studies
(Table I). The reference lists of relevant articles were then manually searched for additional
studies.
Grey literature are publications produced by individuals or organizations, considered to be
outside of the traditional commercial or academic publishing and distribution channels; sources
searched using “spherocytosis” or “splenectomy” include: clinical trial databases (UK Clinical
Trials Gateway; ClinicalTrials.gov),

systematic review registries

(Cochrane Library;

PROSPERO), thesis depositories (Library and Archives Canada; NTLTD, EThOS), health service
agencies (WHO; US CDC, Health Canada; CADTH) and grey literature-specific databases
(OpenGrey; Grey Literature Report). One clinical trial was identified (NCT01276561) but
excluded for lack of relevance and have not yet published any results. Some authors were contacted
by e-mail to provide further details, yet was supplied in only one case [12].
Study screening
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All retrieved studies from database searches were included in the screening process to
create a systematic, precise, and validated search strategy. Records were imported into EPPIReviewer (version 4.5), duplicates removed, and remaining entries were screened on title and
abstract for relevance, and full-text for full consideration. Additionally, eligible studies were
included after reading relevant review articles and their reference lists. A complete list of inclusion
and exclusion criteria is presented in Table II. Studies were not included if they failed to report
on a relevant outcome.
Articles were screened by two independent reviewers in three levels (title, abstract and fulltext) and differences were resolved by consensus. Level 1 (title) screening was based on relevance,
level 2 (abstract) screening ruled in studies based on patient population and outcomes, and level 3
(full-text) screening was carried out on studies that might satisfy all criteria of the PICOS. Level
3 screening inter-rater agreement was 83% (kappa=0.64). Then each article was critically
appraised and a risk of bias assessment was made using Downs and Black checklist [13], which
was originally validated for appraising surgical interventions. Downs and Black score ranges were
given corresponding quality levels as previously outlined: excellent (26–28); good (20–25); fair
(15–19); and poor (≤14) [14]. Articles rated as poor were excluded for severe risk of bias. In total,
14 studies met the sufficient quality criteria and were included in this meta-analysis (Table III)
[12, 15–26].
Meta-analysis and publication bias
Data were extracted into a spreadsheet for analysis. Hemoglobin and percent reticulocytes
were compared using the pre- to post-op difference. When the standard deviation of an estimate
was not reported, it was calculated where possible or estimated from individual patient data. A
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fixed-effects model was used to explore the overall effect of surgery, where each study was
weighted by the inverse variance method (Figure 1). To assess heterogeneity between studies, the
chi-square test and I2 statistic were calculated; an I2 value greater than 75% suggested high
heterogeneity among studies. Publication bias was assessed by inspecting the funnel plot and
Egger's method.
Results
Study Characteristics
From the initial search there were 23 studies included after full-text screening for quality
review (Figure 1). In total, 14 observational studies were included after risk of bias assessment
with a total of 2,224 patients, including one cross-sectional study (Table III) and no identified
trials. The primary reason for exclusion of studies was incomplete data reporting or a high
perceived risk of selection and reporting bias. The funnel plot of hemoglobin concentration
suggested publication bias (Figure 3). However, it is difficult to determine whether this asymmetry
represents a true publication bias, or if there is a true heterogeneity of intervention effects. It is
more likely caused by the small number of studies having few observations. Within each outcome,
the studies do not overlap in patient population based on reported methodology.
Hemoglobin
All studies reported qualitative resolution of anemia, often increasing hemoglobin to
clinically normal values. One year following splenectomy, eight studies reported post-operative
hemoglobin changes for TS and PS, then only four reports concerned PS followed for at least three
to four years (Figure 2). PS significantly increased the hemoglobin concentration by an average
of 2.20 g/dL (95% CI: 1.96 g/dL to 2.45 g/dL; P<0.001) and following TS resulted in an average
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increase of 3.60 g/dL hemoglobin (95% CI: 3.08 g/dL to 4.12 g/dL; P<0.001) (Figure 2A). Three
to four years following PS, there was an average increase of 3.22 g/dL (95% CI: 2.49 g/dL, 3.94
g/dL; P<0.001) (Figure 2B), and after five to six years, there was a significant increase of 2.21
g/dL (95% CI: 1.42 g/dL, 2.99 g/dL; p<0.001) (Figure 2C). A single report followed PS patients
for a decade [15], finding a similar plateau effect.
Reticulocytes
Four studies reporting percent reticulocyte were included for meta-analysis [20–22, 26]
(Figure 4). Absolute reticulocyte counts could not be used for lack of comparison among children
of different ages. Following splenectomy, there is a significant decrease in percent reticulocytes,
though values typically remained above the normal range (1.5%) in both TS and PS at all time
points (Figure 4). Following PS, percent reticulocytes decreased from baseline by an average
decrease of 6.5% (95% CI: -7.4% to -5.6%) after one year (Figure 4A), 12.5% (95% CI: -12.7%
to -12.2%) after three to four years (Figure 4B), and 7.8% (95% CI: -10.7% to -4.9%) after five
to six years (Figure 4C). Percent reticulocytes remain persistently decreased from baseline by
about half to a final value around 4-6%. The profile for TS is more limited but also greater in
magnitude after one year, decreasing by an average of 12.5% (95% CI: -12.7% to -12.2%) to about
2-3% after one year (Figure 4A). This magnitude of effect of TS is heterogeneous, and could be a
result of selection bias if those children undergoing TS had larger spleens or more severe
hemolysis. It is expected that erythropoiesis correlates with the degree of hemolysis and therefore
TS should have a greater effect than PS. The largest study of TS in this review does not include
lab or clinical values [27].
Infections and Mortality
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Fatal events were extremely rare across all reported studies. One 4-year old female died
due to unrelated splenic necrosis 8 weeks following PS [11, 24], in a total of 2,119 reported patients
across 13 studies, and no reported cases of OPSS. The study of 1,657 TS patients [27] used the
Agency for Healthcare Research and Quality’s Pediatric Quality Indicators to profile the safety of
the procedure. The found in-hospital pneumonia was extremely rare (<0.6%). A study of similar
magnitude for PS has yet to be conducted.
Presence of Accessory Spleens
Four studies reported that 4.5% of HS patients have accessory spleen(s) (80/1,770) but the
best estimate in this review is about 3.6% (59/1,657) [27]. This is likely to be underestimated due
to a lack of reporting, but is on the low end of the estimated 4-27% reported for other conditions
([28, 29] and references within). When present, surgeon preferences affect the decision to remove
accessory spleens, where some choose to remove them routinely [26], whereas others do not [18],
with no completion splenectomy after two years in these patients.
Splenic remnant regrowth
The volume of regrowth is highly heterogeneous, ranging from 0-170% of its initial size
[20, 24], consistent with others [30]. Remnant regrowth is does not appear to be associated with
recurring anemia [24, 30], however, regrowth is lowest at younger age and severe disease [24].
Splenomegaly, recurrence of symptoms and secondary splenectomy
Splenomegaly was reported in 241 of 1,716 individuals (14.0%). Only with excessively
large spleens (greater than 1,500 g), do laparoscopic techniques become cumbersome. Recurrence
of symptoms (anemia, jaundice, fatigue or abdominal pain) was not common (5-10%), and in
some, secondary splenectomy was indicated (5%) [15, 16, 20, 23, 24].
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In-hospital complications and adverse surgical events
Paralytic ileus was the most common in-hospital complication (1.5%), followed by urinary
and respiratory complications (1% each), acute pancreatitis and accidental puncture or laceration
during surgery (<1% each) [27]. One HS patient had a sequestration crisis following splenectomy
[21].
Cholelithiasis and cholecystitis
Biliary disease is among the most common associated problem with long-standing
hemolysis. Among TS patients, cholecystectomy was the most common concurrent procedure
(26.7%), of which, 40% suffered from cholelithiasis [27]. The role of prophylactic
cholecystectomy performed during splenectomy in children suffering from HS was questioned in
the late 1990s [31], who found that this was indicated when symptomatic gall stones were present.
The degree of splenectomy does not seem to be associated with cholecystectomy and
cholelithiasis.
Patient health measures and quality of life
Following splenectomy, abdominal pain was improved [19, 20], sleep quality improved
[32] and two studies noted growth spurts in children [15, 32]. Lastly, three studies reported that
quality of life improved using a composite score of some or all of pain, chronic fatigue, or return
to physical exercise [15, 16, 32]. These quality of life metrics were not described using standard
assessment tools and are open to interpretation. Clinical experience would suggest splenectomy is
favourably improves pain and quality of life, despite the residual risk of PS for recurrent anemia.
Length of hospital stay and duration of surgery
While duration of hospital stay and duration of surgery have been reported to be different
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between TS and PS, these data suggests that they are comparable. The length of stay for TS is
between 2-4 days [27]. However, more recent studies on TS find shorter stays of 1-4 days.
Likewise, length of stay for PS was 2-4 days. Surgeries that are uncomplicated and performed
without additional procedures are typically 50-75 minutes. Both length of stay and duration of
surgery will be influenced by the surgeon's technical proficiency and experience.
Discussion
This meta-analysis finds that both total and PS adequately resolve short-term anemia in
pediatric HS patients. There is a general theme that there is longer follow-up data available for PS
patients, and the extent of detailed reporting varies. In the short-term post-operative period,
splenectomy is generally safe and well tolerated, with extremely low risk of death and no reported
cases of OPSS. This agrees with a meta-analysis which included adult hemolytic anemia patients
[33].
Consensus guidelines for which data should be collected during routine monitoring of the
HS patient are needed. For instance, hemoglobin concentration and reticulocytes are inexpensive
and worthwhile to collect. For this reason and based on a pilot search of the literature, they were
used in this review because of their relation to anemia and splenic function, and also that anemia
is an independent risk factor of future cardiovascular disease [34]. The best way forward would be
a discussion among experts with the patient and their family, in order to confirm what are important
and clinically relevant outcomes for the managing clinician and the patient. Ideally, such
information can be collected at regular clinic visits.
Several quality of life instruments measuring of pain, health and functioning exist. A few
examples are the Pediatric Quality of Life Inventory (PedsQL™), WHO International
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Classification of Functioning or the Brief Pain Inventory. A standard inventory should be used
during follow-up visits to better allow for comparison across institutions. Improvement in
abdominal pain and return to physical activity were infrequently described, but can be quickly and
easily determined using a standardized questionnaire. The goal of a related, on-going clinical trial
is to examine the patients' perception of scar formation, suggesting that cosmesis is an important
factor to some patients and their families.
Measures of splenic function need also to be collected and validated prospectively. Pitted
erythrocytes, measured by phase microscopy, are the gold standard of phagocytic function and is
widely available. The normal clinical range is 0–4%, but may increase to 70% in clinically relevant
splenomegaly. Data from sickle cell patients suggest a value of 15% or less is associated with
immune competence and fewer instances of sepsis [35–37]. In contrast, Howell-Jolly bodies
poorly correlate with other measurements [8]. Imaging modalities may be used for functional
assessment. MRI can measure splenic volume in HS [23] and splenosis [29]. Scintigraphic scans
using 99m-technetium labelled heat-damaged, autologous erythrocytes measure splenic function
due to (mostly) splenic sequestration of the cell membranes, and splenic volume. However,
scintigraphy is unlikely to be a cost-effect or common option in the pediatric population, and is
only available in specialized centres. There is the possibility that sequestration-based measures in
HS patients are at risk of increased false positives and could diminish its diagnostic utility [38].
Finally, ultrasonography can assess splenic size, portal hypertension, and gallstones, which may
be an economical, safe, first-line imaging approach.
The extent of splenectomy positively correlates with hematologic improvement. All studies
agreed that TS adequately resolves anemia to normal or near-normal hemoglobin concentrations.
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Hematologic values following PS remain stable for at least five years, and this should also be
expected following TS. There is less erythropoiesis following splenectomy, though percent
reticulocytes remain abnormally elevated due to residual hemolysis. It seems prudent to consider
PS when modest improvements in hemoglobin and reticulocytes are required, and to consider TS
in more severe instances.
Following splenectomy, residual hemolysis increases the risk of gallstone formation, and
symptomatic gall stones or cholecystitis, especially with severe disease or delayed splenectomy
[20]. Secondary TS is indicated when symptoms recur following PS, and is more likely to be
required in severe disease. The genotypic and phenotypic severity of HS should be characterized
to help predict patient outcome, as disease severity is a cumulative effect of spectrin and band 3
protein deficiency, or a relative imbalance in their abundance [39]. The level of methemoglobin
bound to the erythrocyte membrane negatively affects the post-splenectomy hemoglobin
concentration, another possible marker of outcome [39].
An often cited concern for avoiding TS is that the risk of OPSS was perceived to be greater
than that of PS. An older review of 5,902 TS cases produced an estimated post-operative sepsis
rate of 4.4% and a mortality rate of 2.2% [40]. One meta-analysis observed post-operative sepsis
rates of 5-12% for TS and 0–11% for PS [33]. However, these mortality rates included both adult
and pediatric patients across several hemolytic disorders. The reason for the significantly reduced
mortality in pediatric HS over the past two decades is mostly influenced by prophylactic antibiotics
and vaccinations, and to delay elective splenectomy until age five [4, 41]. This delay is even
reflected in the patient demographics (Table III). Furthermore, no case of OPSS in a pediatric HS
patient who has received prophylactic immunization and antibiotics were found.
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Whether the splenic remnant retains immune competency is uncertain. The resident
population of IgM memory B cells in the spleen constitute a major defense against encapsulated
bacteria. However, splenectomy severely reduces this B cell population [9]. Several documented
cases of OPSS or serious bacterial infection in patients with splenosis or accessory spleen tissue
have been documented [29, 42–44], and some cases of fulminant pneumococcal infections occur
more than 20 years after splenectomy [45]. There is no clear correlation that the volume of splenic
regrowth or splenosis offers immune protection, and preliminary findings exacerbate this risk as
immune protection declines with age independent of splenectomy [29, 46]. The immunogenic
response to pneumococci and meningococci vaccination are also less than ideal following
splenectomy performed for congenital hemolytic disorders [46–48]. This scanty data supports the
extra concern noted in a recent review of vaccination guidelines for the care of hyposplenic
individuals [49]. It remains unknown if splenectomized children experience more frequent
bacterial infection in later adulthood.
There are limitations to this review. First, there is a limited length of follow-up. Second,
these reports mostly represent experiences of single institutions, and are often based on a small
patient sample. While these patients experience moderate to severe disease, this review focused
on reports which endeavoured to use systematic collection procedures, such as institutional
reviews, so as to limit some forms of selection bias. While the recovery of hemoglobin, resolution
of hemolysis, prevention of cholelithiasis and the consequent hepatobiliary disease and future risk
of vascular disease in HS patients are all important issues for both the clinician and the patient, the
choice of TS vs PS in achieving an optimal outcome is not yet clear.
This review identifies key opportunities for improving pediatric patient care. First,
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establishing a population-based disease registry for tracking outcomes of HS. Efforts in this
direction have been started by the Splenectomy in Congenital Hemolytic Anemia [21]. Such a
multi-institution collaboration, prospectively following patients, should be able to address
questions of long-term questions of recurrent hemolysis, gall bladder and liver disease, as well as
estimate burden of morbid bacterial infections. It appears feasible based on available data to
conduct a clinical trial comparing PS to TS to examine these outcomes. Second, functional splenic
assessments should be made regularly, possibly incorporating diagnostic imaging to monitor
splenic function and splenic regrowth, gall stones and liver disease. Third, careful monitoring for
history of bacterial infection and vaccination history should continue. Data on serious infection
incidence, lab results and clinical imaging can be incorporated into such a patient registry. Finally,
individualized intervention is advocated with continued surveillance; the optimal choice of
treatment and outcomes should clinically relevant and but confirmed with the patient.
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Figure Legends
Figure 1. Flow diagram of study selection
Figure 2. Meta-analysis of absolute post-operative difference in hemoglobin concentration (g/dL)
from pre-operative baseline. Mean pre- and post-operative hemoglobin concentrations and the
pooled standard deviation are listed. (A) After 6 months to 1 year follow-up, average hemoglobin
concentration increased following PS by 2.20 g/dL (95% CI: 1.96 g/dL to 2.45 g/dL; heterogeneity
I2 = 65.3%) and following TS by 3.60 g/dL (95% CI: 3.08 g/dL to 4.12 g/dL; heterogeneity:
I2 = 0.0%). (B) After 3 to 4 years follow-up, average hemoglobin concentrations increased
following PS by 3.22 g/dL (95% CI: 2.49 g/dL to 3.94 g/dL; heterogeneity I2=0.0%). (C) After 5
to 6 years follow-up, average hemoglobin concentrations increased following PS by 2.21 g/dL
(95% CI: 1.42 g/dL to 2.99 g/dL; heterogeneity I2=44.8%).
Figure 3. Funnel plot of absolute mean difference of measured hemoglobin.
Figure 4. Meta-analysis of post-operative difference in percent reticulocytes from pre-operative
baseline. Mean pre- and post-operative percent reticulocytes concentrations and the pooled
standard deviation are listed. (A) After 6 months to 1 year follow-up, average percent reticulocytes
decreased following PS by 6.5% (95% CI: -7.4% to –5.6%; heterogeneity I2 = 0.0%) and following
TS by 12.5% (95% CI: -12.7% to -12.2%; heterogeneity I2 = 98.7%). (B) After 3 to 4 years followup, average percent reticulocytes decreased following PS by 7.8% (95% CI: -10.7% to -4.9%;
heterogeneity I2 = 0.0%). (C) After 5 to 6 years follow-up, average hemoglobin concentrations
increased following PS by 7.7% (95% CI: -10.7 % to 4.7%; heterogeneity I2=0.0%).
Table Legends
Table I. Search terms
Table II. Inclusion and exclusion criteria.
Table III. Characteristics of included studies.
Supplemental Files
Supplemental Table SI. MOOSE Checklist for Meta-analyses of Observational Studies
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Table I. Search terms.
Domain

Concept

Search terms

Population
of interest

Children (018 yrs)

“Child”&, “Child, Preschool”&, “Infant”&, “Adolescent”&,
youth*, juvenile*, teen*, pediatric*, paediatric*, child*,
preschool*, pre-school, infant*

Indicator

Hereditary
Spherocytosis

“Spherocytosis, Hereditary”&, “Anemia”&, “Anemia,
Hemolytic”&, “Anemia, Hemolytic, Congenital”&,
“Hemolysis”&, “Hemoglobin”&, “Splenomegaly”&,
“Splenectomy”&, “Hypersplenism”&, “Jaundice”&,
spherocyt*, microspherocyt*, splenomega*, splenect*,
accessor*, hypersplen*, anemi*, anaemi*,hemoly*, haemoly*,
hemoglobin*, haemoglobin*, jaundice*

Intervention Splenectomy
(Total vs
Partial)

“Spleen”&, “Splenectomy”&, “Laparotomy”&,
“Laparoscopy”&, “Hand-Assisted Laparoscopy”&,
splenectom*, asplen*, ablat*, laparotom*, laparoscop*, total,
complete, partial, subtotal, sub-total

Outcome

“Treatment Outcome”&, “Hospitalization”&, “Morbidity”&,
“Mortality”&, “Postoperative Complications”&,
“Intraoperative Complications”&, followup* OR follow-up*,
comparison*, morbid*, mortal*, outcome*, complication*,
adverse*

Lab
parameters,
adverse
events,
morbidity,
mortality,
quality of life

Notes: Terms within domains were combined using the OR Boolean operator, while
combinations of domains were combined using the AND operator.
& denotes MeSH major headings. All other search terms were text searches.
* denotes a wildcard.

Table II. Inclusion and exclusion criteria.
Inclusion Criteria
Studies report hereditary spherocytosis patients undergoing any form of splenectomy with preand post-operative hematological parameters or markers of hemolysis, specifically:
hemoglobin concentrations and peripheral reticulocyte proportion.
Studies report adverse events, surgical complications or mortality.
Studies followed a cohort, case-control or case series study design. When case series were
reported, the chart review was conducted in an unbiased manner, such as an institutional
review reporting on all cases of hereditary spherocytosis over a specified period of time.
Data were reported with the value of relative risk (RR), odds ratio (OR) or difference scores
with 95% confidence intervals (CI); or the raw data needed to calculate these statistics.
Studies with English title and abstract (for searching), but whose full-text is available in
English, Italian or French were included.
Exclusion Criteria
Single case reports or case series describing <4 patients. or studies that describe a single
familial experience with HS.
Letters to the editor or commentaries that did not include full data of the splenectomized
patients.
Splenectomies were performed secondary for any other indication than hereditary
spherocytosis, including blunt trauma, thrombocytopenia purpura, sickle cell anemia, or
cholelithiasis.
Data are reported in aggregate of hemolytic anemias, and the spherocytosis-specific data could
not be obtained either from the article text or by correspondence with the author.
Studies which exclusively focus on only “mild” cases of spherocytosis, or adult cases, which
are less likely to require surgical intervention.
Studies that include adult patients, but for which the individual data or subgroup data are not
reported by age.

Table III. Characteristics of included studies.
Study
(Ref)

Study
Design

Sample
Size

Abdullah
2009
[27]

Retrospective
cross-section

1,657

BaderMeunier
2001 [15]

Institutional
case series

Buesing
2011 [16]

Retrospective
cohort

Mariani
2008 [12]

Institutional
case series

Mattioli
2007 [17]

Selected case
series

Morinis
2008 [18]

Retrospective
cohort

Setting &
Location

Period

Splenectomy
& Procedure

Age at
Surgery

M:F

Followup

Risk
of
Biasa

National
registry;
USA

19882004

TS, open

830/819

median: 8.0 y
range: 5-12 y

NR

Single
institution;
France

19851998

PS, open

22/17

8.1 ± 4.3 y (sd)

12-168
mo.

5 pediatric
centres;
Canada &
USA

19902008

PS,
laparoscopy

12/12

7.4 ± 4.2 (sd)

19 mo.

PS, open

19/19

8.2 ± 3.8 y (sd)

48 mo.

121

Single
institution;
Italy

19802008

TS, open

NR

NR

NR

Fair

50

9 pediatric
Jan 1999 - TS,
centres; Italy Dec 2003 laparoscopy

NR

mean: 10.0 y
range: 2-10 y

7-56 mo.

Fair

PS,
laparoscopy

7/2

9.5 ± 4.2 y (sd)

25 mo.

TS,
laparoscopy

7/2

8.6 ± 3.8 y (sd)

25 mo.

39
24
38

9
9

Single
institution;
Canada

20002006

Fair

Good

Fair

Good

Wood 2011 Institutional
case series
[26]

70

TS,
Pediatric
Jan 2000 laparoscopy
centre; USA July 2008
(mostly)

41/29

mean: 8.9 y
range: NR

29-100 d

Rescorla
2007 [19]

Prospective
cohort

111

Single
institution;
USA

Aug 1995
TS (mostly),
- Nov
laparoscopy
2006

NR

mean: 7.7 y
range: 9 mo. 19 y

NR

Fair

Rice 2003
[20]

Prospective
cohort

16

Two
pediatric
institutions;
USA

19932000

NR

7.0 ± 3.4 y (sd)

7-72 mo.

Fair

Rice 2015
[21]

Retrospective
cohort

16
institutions;
Canada &
USA

20052013

19/21

< 18 yr
< 18 yr

NR
NR

Fair

PS,
laparoscopy

NR

5.5 ± 2.8 y (sd)

24 mo.

19
21

PS, open

Good

PS, mixed
TS, mixed

Single
institution;
USA

20022012

TS,
laparoscopy

NR

7.1 ± 3.6 y (sd)

13 mo.

Seims 2013 Retrospective
cohort
[22]

87

Slater 2010 Selected case
series
[23]

9

Single
institution;
USA

May 2005
PS,
- Sept
laparoscopy
2009

5/4

mean: 11.0 y
range: 5-15 y

12-42 mo.

Fair

Stoehr 2006 Prospective
cohort
[24]

31

Single
institution;
Germany

Nov 1996
- Dec
PS, open
2004

17/14

mean: 8.7 y
range: 3-21 y

9-98 mo.

Fair

11

Single
institution;
France

NR

NR

7.9 ± 3.1 y (sd)

6-48 mo.

Fair

Tchernia
1993 [25]

Selected case
series

PS, open

Fair

a

denotes risk of bias assessment using the Downs and Black critical appraisal checklist [13]. Qualitative descriptors
are: excellent (26–28), good (20–25), fair (15–19) and poor (<=14) [14]. Studies with a “poor” score were excluded
during the risk of bias assessment.
TS/PS denotes total or partial splenectomy. NR denotes not reported by author.
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Recommendation

Reporting of background should include
1
Problem definition
2
Hypothesis statement
3
Description of study outcome(s)
4
Type of exposure or intervention used
5
Type of study designs used
6
Study population
Reporting of search strategy should include
7
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10
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13
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16
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17
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Rationale for the selection and coding of data (eg, sound clinical principles or
18
convenience)
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19
interrater reliability)
Assessment of confounding (eg, comparability of cases and controls in studies where
20
appropriate)
Assessment of study quality, including blinding of quality assessors, stratification or
21
regression on possible predictors of study results
22

Assessment of heterogeneity

Description of statistical methods (eg, complete description of fixed or random effects
models, justification of whether the chosen models account for predictors of study
23
results, dose-response models, or cumulative meta-analysis) in sufficient detail to be
replicated
24
Provision of appropriate tables and graphics
Reporting of results should include
25

Graphic summarizing individual study estimates and overall estimate

26

Table giving descriptive information for each study included

27

Results of sensitivity testing (eg, subgroup analysis)

28

Indication of statistical uncertainty of findings
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Reporting of conclusions should include
32
Consideration of alternative explanations for observed results
Yes
Generalization of the conclusions (ie, appropriate for the data presented and within the
33
Yes
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